[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"shoulder-osteoarthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:shoulder-osteoarthritis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,44,70,111,139,165,189,221,242,265,289,323,348,372,397,424,450,473],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100396979","scapular-positioning-in-standing-position-using-sonography-100396979",false,"NCT04449146","Scapular Positioning in Standing Position Using Sonography","3S","Inclusion Criteria:\n\n* Major patients and agreeing to participate in the study after oral and written information.\n* Care course patients for a reverse shoulder arthroplasty on a native shoulder joint\n\nExclusion Criteria:\n\n* Patients under the age of 18\n* Patients refusing to participate in the study\n* Patients whose condition does not allow informed consent\n* Patients who are subject to legal protection (safeguarding of Justice, curatorship, guardianship), persons deprived of their liberty\n* Unaffiliated patients and non-beneficiaries of a health insurance plan","ALL","18 Years","99 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of this study is to analyse the positioning of the scapula in standing position and compared to the supine position (CT scan) in 3 dimensions (3 rotations of the scapula) using a non-radiant, portable system, combining an ultrasound probe with marker and a camera integrated into a Tablet for the three-dimensional location of the marker (probe).",[27,28],"Shoulder Osteoarthritis","Arthropathy Shoulder",[30],"Reverse Shoulder Arthroplasty","RECRUITING","2026-06-25",{"date":34,"type":35},"2026-06-29","ACTUAL",{"date":37,"type":35},"2022-08-31",{"date":39,"type":21},"2026-08-31",{"name":41,"class":42},"University Hospital, Brest","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100347523","rehabilitation-following-reverse-total-shoulder-arthroplasty-100347523","NCT03804853","Rehabilitation Following Reverse Total Shoulder Arthroplasty","Immediate Accelerated Shoulder Rehabilitation Versus a Standard Protocol Following Reverse Total Shoulder Arthroplasty: A Randomized Controlled Trial","RTSA","Inclusion Criteria:\n\n* \\> 55 years of age.\n* Candidate for a primary reverse total shoulder arthroplasty.\n* Capable of completing self-administered questionnaires.\n* Be willing and able to return for all study-related follow-up procedures.\n* Able and willing to give informed consent.\n* Proficient in the English language.\n\nExclusion Criteria:\n\nIn-Clinic:\n\n* Patients planning on undergoing a Primary Reverse Shoulder Total Arthroplasty due to proximal humeral fracture.\n* Previous shoulder surgery including previous total shoulder arthroplasty or reverse total shoulder arthroplasty or hemiarthroplasty, or instability repairs\n* Active bacterial infection of the shoulder.\n* Any concomitant shoulder procedure.\n* Additional ipsilateral or contralateral upper limb pathology that requires active treatment (i.e. surgery or brace).\n* Inflammatory arthropathy.\n* Diagnosed with Rheumatoid arthritis\n* Diagnosed with gout.\n* Subject is on chronic anticoagulation due to a bleeding disorder or has taken anticoagulants within 10 days prior to surgery.\n* Peripheral vascular disease or other vascular disorders that would impair healing.\n* Peripheral neuropathy or other neurological disorders that may impair the patient to ambulate.\n* Patient is on workers compensation.\n* Any condition requiring chemotherapy.\n* Active tobacco user or former tobacco user who is not free of using tobacco for 8 weeks.\n* Uncontrolled Diabetes Mellitus with an HbA1C \\> 7.5%.\n* Current drug or alcohol abuse.\n* Major medical illness (life expectancy less then 2 years or unacceptably high operative risk)\n* Suspicion of cervical radiculopathy or myelopathy.\n* Deltoid insufficiency on physical examination.\n\nIntra-operative:\n\n• Iatrogenic glenoid fracture\n\nPost-operative:\n\n* Neurological injury of the upper extremity.\n* Complications from Primary Reverse Shoulder Total Arthroplasty (i.e. post-operative infection, bleeding, hardware failure).","55 Years",{"count":54,"type":21},74,[24],"Reverse total shoulder arthroplasty (RTSA) has been successful in patients with rotator cuff arthropathy, proximal humerus fractures, failed primary total shoulder arthroplasty or failed hemiarthroplasty, and massive irreparable rotator cuff tear. Patients who undergo an RTSA report pain relief and functional range of motion. It has been more than 20 years since the advent of the RTSA construct but an immediate post-operative rehabilitation with active shoulder range of motion has not been prospectively studied in comparison to the traditional post-operative rehabilitation highlighted by Boudreau et al.12 Investigators plan to prospectively follow our patients following RTSA undergoing an immediate active shoulder rehabilitation (IASR) vs traditional rehabilitation in a randomized controlled fashion. Investigators plan to document clinical outcomes, complications and cost effectiveness out to 1 year.\n\nThe study will hopefully fulfill the Triple Aim model for HealthPartners by improving the health of the population, improve the experience of each individual, and make healthcare affordable by decreasing the total cost of care.",[27],[59,60],"Rehabilitiation","Reverse total shoulder","2026-06-24",{"date":63,"type":35},"2026-06-26",{"date":65,"type":35},"2018-12-12",{"date":67,"type":21},"2027-06-30",{"name":69,"class":42},"HealthPartners Institute",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":88,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":110},"100438054","zimmer-biomet-shoulder-arthroplasty-pmcf-100438054","NCT04984291","Zimmer Biomet Shoulder Arthroplasty PMCF","Zimmer Biomet Shoulder Arthroplasty Long-term Post Market Clinical Follow-up Study","Inclusion Criteria:\n\n* Patient must be 20 years of age or older.\n* Patient must be anatomically and structurally suited to receive shoulder arthroplasty implants.\n* Patient is a candidate for shoulder arthroplasty due to one or more of the following:\n\n  * Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.\n  * Rheumatoid arthritis.\n  * Correction of functional deformity.\n  * Fractures of the proximal humerus, where other methods of treatment are deemed inadequate.\n  * Difficult clinical management problems, where other methods of treatment may not be suitable or may be inadequate.\n* Patient must be able and willing to complete the protocol required follow-up.\n* Patient must be able and willing to sign the IRB\u002FEC approved informed consent.\n* Patient has grossly deficient rotator, (for reverse application)\n\n  * With severe arthropathy and\u002For\n  * Previously failed shoulder joint replacement\n* Patient must have functional deltoid muscle (for reverse application)\n\nExclusion Criteria:\n\n* Patient is unwilling or unable to give consent or to comply with the follow-up program.\n* Patient has any condition which would in the judgement of the Investigator, place the patient at undue risk or interfere with the study.\n* Patient is known to be pregnant or breastfeeding.\n* Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, and\u002For anticipated to be non-compliant).\n* Patient is uncooperative or patient with neurologic disorders who is incapable or unwilling to follow directions.\n* Patient has any sign of infection affecting the shoulder joint or in its proximity which may spread to the implant site.\n* Patient has rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram.\n* Patient has any neuromuscular disease compromising the affected limb that would render the procedure unjustifiable.\n* Patient presents with osteoporosis, which in the opinion of the Investigator, may limit the subject's ability to support total shoulder arthroplasty using the study device.\n* Patient has osteomalacia.\n* Patient has a metabolic disorder that may impair bone formation.\n* Patient has deficient rotator cuff.\n* Patient presents with significant injury to the upper brachial plexus.\n* Patient has paralysis of the axillary nerve.\n* Patient has non-functional deltoid or external rotator muscles.","20 Years",{"count":79,"type":21},584,[24],"The objectives of this study are to confirm the safety, performance, and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation in primary or revision shoulder arthroplasty. These objectives will be assessed using standard scoring systems, radiographic evidence, and adverse event records. Safety of the system will be assessed by monitoring the frequency an incidence of adverse events.",[83,84,27,85,86,87],"Shoulder Fractures","Shoulder Arthritis","Shoulder Deformity","Shoulder Injuries","Shoulder Pain",[89,90,91,92,93,94,95,96,97,98,99],"Total Shoulder Arthroplasty","Glenoid","Humeral Stem","Stem Adapter","Humeral Head","Humeral Bearing","Humeral Trays","Head Adapter","Reverse","Anatomic","Hemi","2026-04-22",{"date":102,"type":35},"2026-04-28",{"date":104,"type":35},"2021-07-28",{"date":106,"type":21},"2033-08-15",{"name":108,"class":109},"Zimmer Biomet","INDUSTRY",17,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":43},"100545429","phase-1-cbd-for-pain-following-orthopedic-shoulder-surgery-100545429","NCT06381791","CBD for Pain Following Orthopedic Shoulder Surgery","Cannabidiol (CBD) As A Pain Adjunct in Orthopedic Surgical Patients: A Randomized Control Trial","CBD","Inclusion Criteria:\n\n* Above the age of 18 years old\n* Undergoing a rotator cuff repair surgery\n* Receiving standard anesthesia during surgery\n* If a subject is of reproductive potential, they must be on effective contraception one month prior, during treatment, and one month following treatment.\n\nExclusion Criteria:\n\n* Under the age of 18 years old\n* History of revision shoulder arthroplasty\n* History of liver disease or impairment\n* Are currently taking valproate or clobazam\n* Are currently taking a moderate\u002Fstrong CYP3A4 or CYP2C19 inhibitor\n* Are currently taking a strong CYP3A4 or CYP2C19 inducer\n* Are currently taking narcotics\n* History of substance\u002Falcohol abuse\n* Those currently or previously under the care of a pain management specialist\n* History of marijuana\u002Fcannabidiol (not including topical) regular use within the past 6 months\n* Allergy related to cannabidiol\n* Allergy related to sesame seeds\n* Pregnancy (As part of standard of care, all female participants will be administered a urine pregnancy test prior to surgery. A negative test result is required to participate in the study.)\n* If you are taking any medications with known risks for suicidal behavior and ideation\n* If you have a diagnosed psychiatric disorder\n* If you are untreated for a diagnosed sleeping disorder\n* If you are actively breastfeeding\n* Patients currently taking central nervous system (CNS) depressants\n* Patients currently taking other drugs with known hepatotoxicity\n* Vulnerable populations.\n\nPatients taking concomitant medications which are substrate of uridine 5'-diphospho-glucuronosyltransferase 1-9 (UGT1A9), uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7), CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and P-gp will be monitored for potential adverse events based on the Epidiolex® label for the concomitant medication being used.",{"count":120,"type":21},80,[122,123],"PHASE1","PHASE2","The goal of the study is to learn if Epidiolex (cannabidiol) works as a additional pain medication in patients who have had orthopedic shoulder surgery. It is also to learn about safe dosages and identify any side effects after surgery.\n\nResearchers will compare Epidiolex to a placebo solution to see if Epidiolex lowers pain after shoulder surgery.\n\nParticipants will:\n\n* track their pain and what medications they use every day in a provided pain diary. A researchers will call every seven days to check on the participant and diary.\n* Complete two short surveys. Once before surgery and once after.\n* Have bloodwork tested after surgery",[27,126],"Rotator Cuff Injuries",[117,128,129],"Cannabidiol","Epidiolex","2026-04-15",{"date":132,"type":35},"2026-04-16",{"date":134,"type":35},"2024-05-24",{"date":136,"type":21},"2027-12-30",{"name":138,"class":42},"The Methodist Hospital Research Institute",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100491168","return-to-golf-after-orthopaedic-surgery-100491168","NCT05675618","Return to Golf After Orthopaedic Surgery","Golfing After Orthopaedic Surgery: a Longitudinal Follow-up (GOLF) Project","Inclusion Criteria:\n\n* Age 18+ years\n* A self-reported golfer\n* Able to consent to treatment\n* Indicated for one of the following surgical procedures: total hip arthroplasty, hip resurfacing, revision hip arthroplasty, total knee arthroplasty, unicompartmental knee arthroplasty, revision knee arthroplasty, total shoulder arthroplasty, reverse shoulder arthroplasty, shoulder resurfacing arthroplasty, revision shoulder arthroplasty\n\nExclusion Criteria:\n\n* Inability to complete follow-up questionnaires\n* Declining operative management\n* No desire to return to golf postoperatively\n* Medical problem that affects the patient's ability to play golf (e.g., angina, shortness of breath, etc.)",{"count":147,"type":21},432,"OBSERVATIONAL","The GOLF study is a multicenter, prospective study with the goal to investigate golfers' return to the sport following hip, knee or shoulder arthroplasty. The prevalence of return to golf, by level of returning to golf will be assessed at 6 weeks, 3 months, 6 months, and 12 months postoperatively. Patients who are active golfers undergoing joint replacement will be identified from outpatient clinics and pre-assessment clinics and given information about the study at least two weeks prior to surgery. Participants in this study must have a desire to return to golf after surgery. Previous studies have only been able to report the return to golf after arthroplasty retrospectively; the prospective nature of this study will allow for a greater understanding of this process.",[151,152,27],"Hip Osteoarthritis","Knee Osteoarthritis",[154],"return to golf, arthroplasty","2026-02-11",{"date":157,"type":35},"2026-02-13",{"date":159,"type":35},"2023-01-09",{"date":161,"type":21},"2026-12",{"name":163,"class":42},"Hospital for Special Surgery, New York",2,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":172,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":43},"100619625","clinical-study-of-myofascial-trigger-pointsmtrps-injection-in-the-treatment-of-shoulder-osteoarthritisoa-100619625","NCT07347054","Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Shoulder Osteoarthritis(OA)","Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Musculoskeletal Pain(CMP), Chronic Migraine and Cervicogenic Headache","Inclusion Criteria:\n\n* Diagnosis of shoulder osteoarthritis with radiographic evidence of osteoarthritis (Kellgren-Lawrence grade 1-4) confirmed by at least two orthopedic surgeons, pain specialists, or general practitioners, with physical examination confirming at least one myofascial trigger point;\n* Disease duration exceeding 3 months;\n* Age ≥ 45 years;\n* Numerical Rating Scale (NRS) score ≥ 3 points despite prior conservative pharmacological treatment;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* History of allergy to trial medications such as corticosteroids;\n* Alcohol abuse; long-term use of opioids (exceeding 2 weeks or more than 3 days per week for over 1 month); suspected use of sedative or analgesic medications; patients on long-term steroid therapy;\n* Severe neurological disorders, significant hepatic or renal dysfunction, heart failure, coagulation abnormalities, gastric ulcer, diabetes, inflammatory rheumatic diseases, etc.;\n* Intra-articular injection within the past 6 months or planned joint replacement surgery;\n* Inability to use pain assessment scales;\n* Presence of local or systemic infection;\n* Pregnant or lactating patients.","45 Years",{"count":174,"type":21},1036,[24],"Chronic musculoskeletal pain (CMP) is a common disease in China, with a high incidence among the elderly, and has a significant impact on patients' quality of life. Shoulder osteoarthritis is a common type of CMP. Currently, both domestic and international studies have confirmed that glucocorticoid injection at myofascial trigger points(MTrPs) can alleviate patients' pain symptoms. MTrPs injection is safe and easy to operate, and can improve the clinical management efficiency of patients with shoulder osteoarthritis. Therefore, we designed a prospective, randomized controlled, blinded outcome, non-inferiority study to compare the long-term clinical efficacy of glucocorticoid injection at myofascial trigger points and complex intra-articular injection in treating shoulder osteoarthritis. Patients will be randomly divided into two groups and receive either glucocorticoid injection at MTrPs or joint cavities. After treatment, patients will be followed up for 2 years. Their NRS scores, WOMAC scores, Patient Global Impression of Change(PGIC) scale, and adverse reactions will be recorded at 2 weeks, 4 weeks, 8 weeks, 12 weeks, and 24 weeks. If the results indicate that the clinical efficacy of myofascial trigger point injection for shoulder osteoarthritis is not inferior to that of injection at intra-articular injection, it will provide a safe and simple treatment option that is easy to promote for patients who do not respond to conservative treatment.",[178,179,27],"Myofascial Trigger Points","Chronic Musculoskeletal Pain","2026-01-11",{"date":182,"type":35},"2026-01-16",{"date":184,"type":35},"2025-12-01",{"date":186,"type":21},"2027-06-01",{"name":188,"class":42},"Beijing Tiantan Hospital",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":196,"sex":16,"minAge":17,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":202,"conditions":203,"keywords":207,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":43},"100505972","phase-4-comparison-of-interscalene-catheter-to-single-injection-interscalene-blocks-for-total-shoulder-arthroplasties-100505972","NCT05868330","Comparison of Interscalene Catheter to Single Injection Interscalene Blocks for Total Shoulder Arthroplasties","A Feasibility Randomized Control Comparison of Peripheral Interscalene Catheter to Liposomal Bupivacaine Single Injection for Interscalene Blocks Used in Pain Control for Total Shoulder Arthroplasties","Inclusion Criteria:\n\nPatients who have or are:\n\n1. Orthopedics service patients having reverse shoulder replacement surgery\n2. ASA class I, II, or III.\n3. Patients at least 18 years old but less than 90 years old.\n4. Patients giving informed consent.\n5. Non-Emergency Surgery\n\nExclusion Criteria:\n\nPatients who have or are:\n\n1. An inability to cooperate during the block placement.\n2. Patients who do not meet criteria for a regional block: such as those on anti-coagulation,\n3. Significant pulmonary disease or allergy to medications used for peripheral nerve blocks (Exparel, Bupivacaine and Ropivacaine)\n4. Neuropathy of the planned extremity to block\n5. Documented Kidney Failure\n6. Documented Liver Failure\n7. A lack of or inability to give informed consent.\n8. Currently incarcerated.\n9. Pregnant\n10. Unable to communicate in English\n11. Chronic pre-operative opioid use (greater than 20 MME opioid used)\n12. Fracture\n13. Revision surgery",true,"90 Years",{"count":199,"type":21},56,[201],"PHASE4","Comparison of post-operative pain after total shoulder surgery. The Principle Investigator will be comparing Exparel single shot block to Interscalene catheter",[204,205,206,27],"Post Operative Pain","Anesthesia","Nerve Block",[206,208,209,210,211],"Shoulder Replacement","Interscalene block","Peripheral Nerve Catheter","Exparel","2025-11-05",{"date":214,"type":35},"2025-11-10",{"date":216,"type":35},"2024-08-19",{"date":218,"type":21},"2027-01",{"name":220,"class":42},"Melinda Seering",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":43},"100491161","phase-4-prp-for-glenohumeral-osteoarthritis-100491161","NCT05675527","PRP for Glenohumeral Osteoarthritis","Outcomes Following Single Injections of Low-dose Platelet-rich Plasma (PRP), High-dose PRP, or Saline in Patients With Glenohumeral OA: a Randomized Controlled Trial","Inclusion Criteria:\n\n* 18-100 years old\n* Average NRS pain greater than or equal to 5\u002F10 as a direct result of glenohumeral osteoarthritis (any severity: mild, moderate, or severe) and\u002For chondral lesion or loss\n* At least 3 months of pain after onset of symptoms that has failed conservative treatments, including physical therapy\n* MRI of the affected joint\n* Transient relief of symptoms after a diagnostic intra-articular injection into the joint\n* Email address or network access\n\nExclusion Criteria:\n\n* Inability to hold non-steroidal anti-inflammatory drugs for 2 weeks prior and 1 month after the injection\n* Prior platelet-rich plasma injection\n* Steroid injection within 3 months of the initial injection\n* Hyaluronic acid within 6 months of the initial injection\n* Involved in workers' compensation or active litigation involving the affected joint\n* History of Plavix use\n* Known uncontrolled systemic illness (uncontrolled diabetes, HIV, vasculitis, autoimmune\u002Fautoinflammatory disease)\n* Presence of acute fractures or gross mechanical deformities\n* Concurrent \"uncontrolled\" cervical disorders","100 Years",{"count":230,"type":21},135,[201],"The glenohumeral joint is the third most common large joint to be affected by OA. Conservative treatments include physical activity, corticosteroid injections, and medications. PRP is an emerging treatment that has shown efficacy in different musculoskeletal conditions. The use of PRP for glenohumeral OA has been described sparingly in the literature but has shown efficacy in a couple studies and case reports. However, all of the previous studies investigating PRP for glenohumeral OA have focused on low-dose PRP preparations (\\~3X), and none have compared PRP treatment to saline treatment. This study aims to compare outcomes following single injections of low-dose PRP, high-dose PRP, or saline in patients with glenohumeral osteoarthritis.",[27],"2025-10-01",{"date":236,"type":35},"2025-10-06",{"date":238,"type":35},"2023-05-02",{"date":240,"type":21},"2026-09-01",{"name":163,"class":42},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":249,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":254,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":4},"100597590","comparison-between-anatomic-shoulder-arthroplasty-hemiarthroplasty-and-reverse-shoulder-arthroplasty-100597590","NCT07060469","Comparison Between Anatomic Shoulder Arthroplasty, Hemiarthroplasty, and Reverse Shoulder Arthroplasty.","Comparative Analysis of Anatomic Shoulder Arthroplasty, Hemiarthroplasty, and Reverse Shoulder Arthroplasty in Patients Over 70: A Retrospective Single Unit Single Surgeon Study","Inclusion Criteria:\n\nAll genders Over 70 All ethnic groups Anatomic \u002F Reverse \u002F Hemi shoulder replacement\n\nExclusion Criteria:\n\nUnder 70 years of age Shoulder replacement for trauma\u002Ftumour","70 Years",{"count":251,"type":21},110,"This study aims to evaluate outcomes in patients over 70 years of age who underwent anatomic shoulder arthroplasty, hemiarthroplasty, or reverse shoulder arthroplasty, focusing on revision rates, rotator cuff integrity as primary and Oxford Shoulder Scores as secondary outcome measures.",[27],"NOT_YET_RECRUITING","2025-07-01",{"date":257,"type":35},"2025-07-11",{"date":259,"type":21},"2025-07-31",{"date":261,"type":21},"2025-12-31",{"name":263,"class":264},"Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust","OTHER_GOV",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":273,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":288},"100469669","clinical-evaluation-of-reverse-versus-anatomic-shoulder-arthroplasty-techniques-in-the-treatment-of-osteoarthritis-100469669","NCT05395819","Clinical Evaluation of Reverse Versus Anatomic Shoulder Arthroplasty Techniques in the Treatment of Osteoarthritis","Clinical Evaluation of Reverse Versus Anatomic Shoulder Arthroplasty Techniques in the Treatment of Osteoarthritis: A Pilot Randomized Control Trial","CERVASA","Inclusion Criteria:\n\n1. Patients who have failed standard non-surgical management of their shoulder osteoarthritis who would benefit from a shoulder arthroplasty. Failed medical management will be defined as persistent pain and disability despite adequate standard non-operative management for 6 months. Medical management will be defined as:\n\n   1. The use of drugs including analgesics and non-steroidal anti-inflammatory drugs\n   2. Physiotherapy consisting of stretching, strengthening and local modalities (ultrasound, cryotherapy, etc.)\n   3. Activity modification\n2. Imaging, and intra-operative findings confirming advanced gleno-humeral cartilage loss\n3. Patients may present with a glenoid deficiency and \\>15 degrees of retroversion\n4. 65 years of age and older\n\nExclusion Criteria:\n\n1. Active joint or systemic infection\n2. Rotator cuff arthropathy\n3. Need for an augmented glenoid component or a bone graft to correct version to within 10 degrees of neutral\n4. Retroversion cannot be surgically corrected to within 10 degrees of neutral with a \"high- side\" ream technique\n5. Significant muscle paralysis\n6. Charcot's arthropathy\n7. Major medical illness (life expectancy less than 1 year or unacceptably high operative risk)\n8. Active Workers Compensation Board (WCB) claim\n9. Unable to understand the consent form\u002Fprocess\n10. Psychiatric illness that precludes informed consent\n11. Unwilling to be followed for the duration of the study\n12. History of previous shoulder surgery on affected side","65 Years",{"count":275,"type":21},40,[24],"Osteoarthritis (OA) is the most common form of arthritis, affecting millions of people worldwide and it is common in an aging population. Surgical shoulder replacement (arthroplasty) is typically considered when non-surgical measures, such as physiotherapy or medication, have failed. There are two commonly performed surgical replacement procedures in patients who have advanced shoulder OA, and are 65 years of age and older: \"Total Shoulder replacement or Arthroplasty (TSA)\" and \"Reverse Total Shoulder Arthroplasty (RTSA)\".\n\nFew studies have compared the two procedures. Surgeons face uncertainty regarding which procedure to perform in patients 65 years of age and older. This pilot Randomized Controlled Trial (RCT) will compare the \"TSA\" and \"RTSA\" procedures, in patients 65 years of age and older. Participants will be assigned at random, (like flipping a coin), to one of the two groups (TSA or RTSA). The overall goal of this pilot study is to determine which procedure produces better functional and quality of life outcomes with fewer complications within the first 12-months after surgery. Moreover, pilot data will help determining the feasibility of conducting a larger trial comparing TSA versus RTSA surgical management in 65 years of age and older participants with advanced shoulder OA.",[27],"2025-05-23",{"date":281,"type":35},"2025-05-30",{"date":283,"type":35},"2022-05-30",{"date":285,"type":21},"2026-05-30",{"name":287,"class":42},"University of Alberta",8,{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":22,"phases":298,"briefSummary":299,"conditions":300,"keywords":303,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":43},"100569379","could-a-feedback-device-help-manage-work-related-shoulder-disorders-100569379","NCT06693479","Could a Feedback Device Help Manage Work-related Shoulder Disorders?","Could a Feedback Device Help Manage Work-related Shoulder Disorders? - Protocol of a Mixed Methods Pilot Study","Inclusion Criteria:\n\n1. Adult (≧ 18 years) employed full-time (minimum of 30 hours per week).\n2. Experiencing work-related shoulder disorders (WRSDs), with minimal score of 14 points on the for the abbreviated version of the Disability of the Arm Shoulder and Hand questionnaire (QuickDASH), stemming from a diagnosis of rotator cuff-related shoulder pain (RCRSP), shoulder osteoarthritis (SOA) or rheumatoid arthritis (RA) involving the shoulder.\n3. Symptoms persisting for more than 6 weeks.\n\nDiagnosis-specific criteria:\n\n1. RCRSP: diagnosis requires meeting three positive criteria, including the presence of a painful arc in abduction, a positive Neer sign, Hawkins-Kennedy test, or Jobe Test, pain with resisted humeral external rotation;\n2. SOA: diagnosis based on clinical findings (e.g., activity-related pain, reduced range of motion particularly external rotation and function, worsening night\u002Frest pain) and radiologic findings (e.g., osteophytes, joint space narrowing, subchondral sclerosis, cyst formations, and humeral head deformities);\n3. RA involving the shoulder: confirmed diagnosis according to the American College of Rheumatology criteria.\n\nBoth SOA and RA diagnoses will be confirmed by a physician.\n\nExclusion Criteria:\n\n1. clinical signs of a massive rotator cuff tear (e.g., pseudoparesis or pseudoparalysis, passive elevation intact but active limited to \\\u003C90°, without neurologic deficit);\n2. acute traumatic rotator cuff tears, fractures, adhesive capsulitis (characterized by night pain, pain with sudden or unexpected movements, global loss of active and passive range of motion), or shoulder instability (evidenced by a combination of orthopaedic tests such as apprehension and relocation tests, Jerk, Kim and posterior tests, along with and clinical signs like neuromuscular function impairment, history of instability, lesion mechanisms, worries that their shoulder could dislocate during activities);\n3. distal neurovascular symptoms (e.g., thoracic outlet syndrome, venous thromboembolism);\n4. previous shoulder surgery;\n5. corticosteroid injection administered within the past 3 months;\n6. symptomatic acromioclavicular joint pathology;\n7. currently receiving conservative management for their shoulder pain (excluding medication for RA and OA),\n8. absenteeism from work (unable to work at least 30 hours per week or on sick leave).",{"count":297,"type":21},42,[24],"Work-related shoulder pain is a common problem with significant socio-economic repercussions. The impact of these disorders on workers is considerable, particularly in terms of pain, disability and reduced quality of life. Several occupational factors may explain the onset of these disorders, such as changes in the work environment, physical demands, psychosocial factors specific to the occupational context and the age of workers. The lack of quantitative measurement tools to assess the physical demands of work over an extended period of time is sorely felt. Recently, our team developed a wearable feedback device, similar to a watch worn on the arm, which measures shoulder movements and muscle activity, transforming this real-time data into clinical indicators. These indicators provide immediate feedback to workers, enabling them to better understand the physical demands of their tasks and adapt accordingly. If this device proves effective in reducing physical demands, it could become a valuable tool for guiding workplace assessments and interventions. However, this device has not yet been tested on workers with shoulder pain. For this reason, a two-part pilot study is needed to understand user needs, assess ease of use and the feasibility of implementing the device. The first component will consist of a pilot clinical trial involving 42 workers suffering from shoulder pain, divided into two groups: one group will use the feedback device for 2 weeks, while the other group will continue to work without intervention. The second phase will analyze the experience of participants who have used the device.",[301,27,302],"Rotator Cuff-related Shoulder Pain","Rheumatoid Arthritis (RA)",[304,305,306,307,308,309,310,311,312,313],"Technology","Shoulder pain","Feasibility","Workers","Feedback","Pilot","Randomized controlled trial","Focus group","Device","Mixed methods study","2025-05-05",{"date":316,"type":35},"2025-05-08",{"date":318,"type":35},"2025-03-01",{"date":320,"type":21},"2026-07",{"name":322,"class":42},"Laval University",{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":333,"conditions":334,"keywords":335,"overallStatus":254,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":43},"100556053","optimizing-recovery-after-reverse-shoulder-arthroplasty-with-a-personalized-mobile-health-application-100556053","NCT06520085","Optimizing Recovery After Reverse Shoulder Arthroplasty With a Personalized Mobile Health Application","TRAPP","Inclusion Criteria:\n\n* adults undergoing elective reverse shoulder arthroplasty\n\nExclusion Criteria:\n\n1\\) do not own or are not able to operate a smart device; 2) are scheduled for revision surgery; 3) have a fracture as primary diagnosis; 4) an additional muscle transfer needs to be performed; or 5) are unable to read and understand the Dutch language.",{"count":331,"type":21},170,[24],"Background: Mobile health (mHealth) - the use of medical applications in healthcare settings - include tools that can support self-management after surgery and thereby contribute to early postoperative recovery. Providing patients with timely and interactive information through mHealth is hypothesized to positively influence recovery after reverse shoulder arthroplasty (RSA).\n\nAim: The aim of this study is to determine the effectiveness of interactive and personalized information and rehabilitation protocol with a mobile application compared to generic information and generic rehabilitation protocol (standard care) on postoperative recovery in patients undergoing primary RSA.\n\nMethods and analysis: A multicentre randomised controlled trial will be conducted in two Dutch hospitals. In total 170 patients undergoing elective, primary RSA will be included. Participants will be randomly allocated to one of the two groups on a 1:1 ratio. The intervention group will receive interactive postoperative information on a daily basis. The control group will receive standard care. The primary outcome is defined as functional recovery measured using the Oxford Shoulder Score (OSS) at 6 weeks. Secondary outcomes are: pain, physical functioning, quality of life, length of stay, complications, treatment satisfaction and app use. The between group difference will be analysed using linear mixed-effects regression.",[27],[30,336,337,338],"mHealth","Perioperative Care","Rehabilitation","2024-07-22",{"date":341,"type":35},"2024-07-25",{"date":343,"type":21},"2024-08-01",{"date":345,"type":21},"2026-12-31",{"name":347,"class":42},"VieCuri Medical Centre",{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":357,"conditions":358,"keywords":359,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":371},"100540674","aetos-shoulder-system-100540674","NCT06319911","AETOS Shoulder System","AETOS Shoulder System Post Market Clinical Investigation","Inclusion Criteria:\n\nPatients must meet all the following criteria to be included in the study:\n\n1. Patient is at least 18 years of age at the time of consent and skeletally mature.\n2. Patient is undergoing a primary elective anatomic or reverse shoulder replacement surgery for one of the following indications:\n\n   * Rheumatoid arthritis, and\u002For\n   * Traumatic arthritis (Post Traumatic arthritis), and\u002For\n   * Non-inflammatory degenerative joint disease, and\u002For\n   * Correction of functional deformity.\n3. Patient is willing and able to accommodate all study-related procedures and visits detailed in the protocol \\& cooperate in the standard of care post-operative therapy.\n4. Patient is geographically stable and willing to return to the study site for all follow-up visits.\n5. Patient has been adequately informed of risks and requirements of the study and is willing and able to provide informed consent for participation.\n\n   \\-\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria will not qualify for participation in the trial:\n\n1. Patient has a contraindication to AETOS.\n2. Patient is undergoing a revision shoulder replacement surgery including total or partial arthroplasty.\n3. Patient is indicated for a Hemiarthroplasty.\n4. Patient has traumatic injury or a fracture.\n5. Patient has uncontrolled diabetes with a hemoglobin A1C of 7.5 or greater.\n6. Patient has comorbidities\u002Fconditions that preclude proper healing\u002Ffixation of the implant.\n7. Patient has poor quality or insufficient bone stock to support the implant.\n8. Patient has poor bone quality where there could be considerable migration of the implant and\u002For a chance of fracture.\n9. Patient has rapid joint destruction, marked bone loss or bone resorption (e.g., severe osteoporosis).\n10. Patient has osteomalacia.\n11. Patient has muscular, neurologic, or vascular deficiencies that may compromise the outcome of the shoulder replacement surgery.\n12. Patient has a known sensitivity, allergic reaction, and\u002For known allergies to one or more of the implanted materials.\n13. Patient has a distant foci of infection which may spread to the implant site, active local or systemic infection, sepsis, or osteomyelitis.\n14. Patient has an elevation of sedimentation rate, elevation of WBC count, or marked shift in WBC differential count unexplained by other disease.\n15. If reverse shoulder arthroplasty, patient has a non-functional deltoid or external rotator muscles.\n16. If reverse shoulder arthroplasty, patient has a significant injury to the upper brachial plexus.\n17. If reverse shoulder arthroplasty, patient has paralysis of the axillary nerve.\n18. Patient is uncooperative, has a neurologic disorder and is not capable of following directions, or is a vulnerable subject per ISO 14155 (i.e., individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response).\n19. Patient is pregnant or plans to become pregnant during the follow-up period.\n20. Patient has a Body Mass Index (BMI) of \\>35kg\u002Fm2 or a BMI that may compromise the outcome of the shoulder replacement surgery.\n21. Patient has anticipated activities which would impose high stresses on the implant and its fixation or has a high likelihood of a fall.\n22. Patient is a known smoker, vaper, alcohol abuser, or drug abuser within 180 days of consent.\n23. Patient has participated previously in this clinical trial and was withdrawn.\n24. Patient is participating in another device or drug trial or observational competitive study.",{"count":356,"type":21},220,"The goal of this study is to confirm the safety and performance of the AETOS Shoulder System for USA adoption. This is a prospective, open, adaptive, non-comparative, multi-centre investigation enrolling a maximum of 220 subjects in 2 cohorts (anatomic and reverse) at up to 15 sites. No intra-study comparator group will be included, and there will be no randomization",[27,84],[360,361],"Shoulder","arthroplasty","2024-05-06",{"date":364,"type":35},"2024-05-07",{"date":366,"type":35},"2024-03-05",{"date":368,"type":21},"2030-08-30",{"name":370,"class":109},"Smith & Nephew, Inc.",5,{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":22,"phases":381,"briefSummary":382,"conditions":383,"keywords":385,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":395,"locationsCount":43},"100470607","comparison-of-the-analgesic-effect-of-2-shoulder-infiltrations-100470607","NCT05408065","Comparison of the Analgesic Effect of 2 Shoulder Infiltrations","A Randomized Single-blinded Clinical Trial of the Efficacy of Intra-articular Infiltration of Cingal (Sodium Hyaluronate\u002FTriamcinolone) Versus Cortisone (Triamcinolone) in Patients With Osteoarthritis of the Shoulder.","Inclusion Criteria:\n\n* A clinical examination that confirms the radiological diagnosis of moderate to severe primary shoulder osteoarthritis, stage II and above, according to the Samilson-Prieto classification.\n* Patients aged between 20 and 90 years.\n* A patient with bilateral shoulder osteoarthritis will choose the side of the infiltration, only one side can be chosen to participate in the study.\n* The patient must have a clinical pain threshold of a minimum of 4\u002F10 on the visual analogue scale.\n* The patient must have the cognitive ability to read and fill out the questionnaires.\n* The patient must be able to read and understand French or English\n\nExclusion Criteria:\n\n* Presence of a transfixing rotator cuff tear assessed on MRI.\n* No previous shoulder reconstruction surgery.\n* Pregnant woman.\n* A patient who has received a cortisone infiltration within 6 months prior to the start of the study.\n* A patient who has received a platelet-rich plasma or a hyaluronic acid infiltration within 12 months prior to the start of the study.\n* Diagnosis of avascular necrosis.\n* Disease affecting the studied joint (systemic inflammatory disease, history of septic arthritis, osteonecrosis, etc.)\n* Suspicion or presence of active local infectious process.\n* Presence or suspicion of neoplasia or local metastasis.\n* Severe trauma to the shoulder ( ≤ 3 months)\n* Significant cognitive impairment or insufficient language proficiency to adequately answer the questionnaires.\n* Any other serious medical condition that does not allow participation in the study or may be a contraindication to cortisone injection.",{"count":380,"type":21},84,[24],"For patients suffering of osteoarthritis, only analgesic treatments such as anti-inflammatory drugs and cortisone infiltrations provide significant but temporary relief of their pain. The objective is to compare the analgesic effect of 2 infiltrations: Cingal (sodium hyaluronate and triamcinolone) versus cortisone (triamcinolone). It is anticipated that the Cingal infiltration will have a greater analgesic effect than a simple cortisone infiltration in patients with moderate to severe osteoarthritis of the shoulder.\n\nMethod:\n\n* Randomized controlled trial\n* Monocentric\n* Randomization will be done using sealed envelopes",[384,27],"Infiltration",[386,387,388],"infiltration","Osteoarthritis","hyaluronic acid","2024-02-09",{"date":391,"type":35},"2024-02-12",{"date":393,"type":35},"2022-11-15",{"date":161,"type":21},{"name":396,"class":42},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":398,"slug":399,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":11,"sex":16,"minAge":172,"maxAge":405,"enrollmentInfo":406,"targetDuration":4,"studyType":22,"phases":408,"briefSummary":409,"conditions":410,"keywords":412,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":164},"100518037","does-bio-rsa-provides-superior-clinical-outcome-compared-to-conventional-rsa-100518037","NCT06025331","Does BIO-RSA Provides Superior Clinical Outcome Compared to Conventional RSA?","From Cuff Arthropathy to Reverse Shoulder Arthroplasty - a Multicentre Randomized Control Trial (Study 1: Does BIO-RSA Provides Superior Clinical Outcome Compared to Conventional RSA?).","CARS-1","Inclusion Criteria:\n\n* Eligible for primary RSA due to OA, massive RC tear, failed RC repair or post-instability osteoarthritis\n* Able to read or write Norwegian\n\nExclusion Criteria:\n\n* Severe osteoporosis\n* Osteonecrosis of the humeral head\n* Dementia\n* Poor deltoid function\n* Revision surgery\n* ASA IV\n* Suspected chronic infection\n* Acute fracture","80 Years",{"count":407,"type":21},130,[24],"The goal of this clinical trial is to compare two different types of reverse shoulder replacements. Researchers will compare a conventional reverse shoulder replacement with a lateralized reverse shoulder replacement to see if there is a difference in how well the patients function after two years.",[411,27],"Arthroplasty, Replacement, Shoulder",[30,413,414],"BIO-RSA","Orthopedic surgery","2023-11-06",{"date":417,"type":35},"2023-11-07",{"date":419,"type":35},"2023-09-15",{"date":421,"type":21},"2033-08-01",{"name":423,"class":42},"Lovisenberg Diakonale Hospital",{"id":425,"slug":426,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":16,"minAge":172,"maxAge":405,"enrollmentInfo":432,"targetDuration":4,"studyType":22,"phases":434,"briefSummary":435,"conditions":436,"keywords":438,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":43},"100518046","is-mio-rsa-noninferior-to-bio-rsa-when-it-comes-to-mechanical-implant-stability-100518046","NCT06025448","Is MIO-RSA Noninferior to BIO-RSA When it Comes to Mechanical Implant Stability?","From Cuff Arthropathy to Reverse Shoulder Arthroplasty - a Multicentre Randomized Control Trial (CARS 2: Is MIO-RSA Noninferior to BIO-RSA When it Comes to Mechanical Implant Stability Measured With CT-based Motion Analysis (CTMA)?).","CARS-2","Inclusion Criteria:\n\n* Eligible for primary RSA due to OA, massive RC tear, failed RC repair or post-instability osteoarthritis\n* massive glenoid medialization\n* Able to read or write Norwegian\n\nExclusion Criteria:\n\n* Severe osteoporosis\n* Osteonecrosis of the humeral head\n* Dementia\n* Poor deltoid function\n* Revision surgery\n* ASA IV\n* Suspected chronic infection\n* Acute fracture",{"count":433,"type":21},20,[24],"This clinical trial will investigate whether metallic lateralization in reverse shoulder arthroplasty is as stable as bony lateralization during the first two postsurgical years, measured with CT-based motion analysis (CTMA).",[437,27],"Arthroplasty Complications",[439,413,440,441,442,443],"Reverse shoulder arthroplasty","MIO-RSA","Bony lateralization","Metallic lateralization","Orthopedic Surgery",{"date":417,"type":35},{"date":446,"type":35},"2023-10-30",{"date":448,"type":21},"2033-03-01",{"name":423,"class":42},{"id":451,"slug":452,"hasResults":11,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":196,"sex":16,"minAge":458,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":22,"phases":461,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":43},"100499850","retroversion-in-reverse-shoulder-arthroplasty-100499850","NCT05788614","Retroversion in Reverse Shoulder Arthroplasty","In a Reverse Shoulder Arthroplasty, Does Function Depend on the Humeral Version? A Prospective Randomized Study.","RV-RSA","Inclusion Criteria:\n\n* patients \\> 60 years\n* primary rotator cuff arthropathy\n* implantation of reverse shoulder arthroplasty\n\nExclusion Criteria:\n\n* previous surgeries in the shoulder\n* post-traumatic arthropathy","60 Years",{"count":460,"type":21},90,[24],"The goal of this clinical trial is to compare function in reverse shoulder arthroplasty (RSA) using two different degrees of humeral retroversion (RV). The main question it aims to answer is:\n\n• Does external rotation improves when using a higher retroversion?\n\nParticipants will randomly receive a 0 degree or 30 degree RV for their RSA.\n\nThey will be followed for two years and clinical outcomes will be recorded and analyzed.",[27],"2023-03-24",{"date":466,"type":35},"2023-03-29",{"date":468,"type":35},"2022-06-30",{"date":470,"type":21},"2026-06-30",{"name":472,"class":264},"Hospital Universitario Reina Sofia de Cordoba",{"id":474,"slug":475,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":148,"phases":4,"briefSummary":482,"conditions":483,"keywords":490,"overallStatus":254,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":4},"100463414","s-11-smr-tt-hybrid-glenoid-and-cementless-finned-short-stem-100463414","NCT05314387","S-11 SMR TT Hybrid Glenoid and Cementless Finned Short Stem","A Multicentre, Prospective Clinical Study Analysing Outcomes of Shoulder Arthroplasty With SMR TT Hybrid Glenoid With or Without SMR Cementless Finned Short Stem","Inclusion Criteria:(Key)\n\n* Both genders;\n* Age ≥ 18 years old;\n* Full skeletal maturity;\n* Life expectancy over 5 years;\n* Patient is requiring primary unilateral arthroplasty based on physical examination and medical history;\n* Good bone quality evaluated by the Investigator and the intraoperative evaluation;\n* A diagnosis in the target shoulder of one or more of the S-11 SMR TT Hybrid Glenoid and Cementless Finned Short Stem Version Sep 2021 2.0 Confidential Page11 following:\n\n  1. Primary osteoarthritis;\n  2. Secondary osteoarthritis;\n  3. Post-traumatic arthritis;\n  4. Rheumatoid arthritis;\n  5. Avascular necrosis\n  6. acute fractures of the humeral head that cannot be treated with other fracture fixation methods;\n  7. cuff tear arthropathy (only in combination with CTA Heads);\n  8. Glenoid arthrosis without excessive glenoid bone loss: A1, A2 and B1 according to Walch classification.\n\nExclusion Criteria (Key):\n\n* Patient requiring revision shoulder arthroplasty;\n* Osteoporosis with a history of non-traumatic fractures;\n* Steroid injections within the previous 3 months;\n* Contralateral shoulder replacement within the previous 3 months;\n* Significant proven or suspicious infection of the target shoulder or any serious infectious disease before the study according to the Investigator;\n* Significant neurological or musculoskeletal disorders that may compromise functional recovery;\n* Not recovered axillary nerve palsy;\n* Non functioning deltoid muscle;\n* Known or suspicious hypersensitivity to the metal or other components and materials of the implant;\n* Participation in any experimental drug\u002Fdevice study within the 6 months prior to the preoperative visit;\n* Women of childbearing potential who are pregnant, nursing, or planning to become pregnant.\n\nThese are key eligibility criteria, other eligibility criteria apply.",{"count":481,"type":21},100,"Post-market, prospective, non randomized, open label, multicentre, clinical study analysing outcomes of shoulder arthroplasty with SMR TT Hybrid Glenoid with or without SMR Cementless Finned Short Stem",[84,27,484,387,485,486,487,488,489],"Arthrosis","Rheumatoid Arthritis","Arthroplasty","Avascular Necrosis","Humeral Fractures","Cuff Tear Arthropathy",[491,208,492,493],"Shoulder Joint","Arthritis with rotator cuff tear","Post traumatic fracture sequele","2022-03-29",{"date":496,"type":35},"2022-04-06",{"date":498,"type":21},"2022-04",{"date":500,"type":21},"2029-04",{"name":502,"class":109},"Limacorporate S.p.a"]